Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3052230 in FGFR1-amplified squamous NSCLC and mesothelioma
NL-OMON44632Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of FP-1039 in non-small cell lung cancer (NSCLC) and mesothelioma (3 arms), sponsored by GSK. Primary endpoints: Adverse events, Maximum tolerated dose and 2 more. Started Sep 2014; status: active, not recruiting.
02
Drugs
FP-1039
03
Conditions
non-small cell lung cancer (NSCLC)mesothelioma
Beyond the preview
Go deeper on NL-OMON44632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44632.